+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 19 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are investigating metastatic colorectal cancer mCRC patients who have a specific genetic change called the BRAFV600E mutation. This rare subtype of mCRC often shows poor response to current treatments and has a generally poor outlook. The study aims to collect detailed clinical data and biological samples to better understand this condition, including how patients respond to treatments and what factors predict their survival. It focuses on real-world treatment outcomes and biological markers that might influence therapy choices and resistance. Participants will provide blood samples at multiple times during their treatment, including before and during the first three treatment cycles, at 3 and 6 months after starting each treatment line, and when disease progression occurs following certain therapies. The study gathers up to 390 mL of blood per participant over time to analyze circulating tumor DNA and immune environment factors. This observational approach will help researchers identify biomarkers related to treatment response and disease progression. During the study, participants clinical progress and survival will be tracked for up to five years. Researchers will review overall survival from diagnosis to death and assess how prognostic markers relate to progression-free survival and response to treatments. The study involves collecting tumor tissue samples and blood tests, along with routine follow-up visits. All data collected will contribute to understanding BRAFV600E mCRC and improving future treatment strategies.

Age: 18Years +All GendersPhase Not Applicable
45 locations
O

Actively Recruiting

Researchers are evaluating the safety and effects of Abrocitinib in adults with moderate to severe atopic dermatitis, a long-lasting skin condition that causes inflammation, redness, and irritation. This observational study aims to understand how Abrocitinib works in real-life clinical settings for patients aged 18 and older who do not have other medical conditions that would prevent them from taking the medication. All participants will take Abrocitinib as a daily tablet and may also use medicated topical treatments for their condition. The study lasts 24 months, during which participants will be monitored regularly. They will visit the study clinic approximately five times, about once every 4 to 6 months, to report their experiences and health status while using the medication. Throughout the study, researchers will assess participants using various measures such as skin condition scores, itching severity scales, and sleep quality assessments. They will also track treatment adherence, any changes in medication dosage, and any side effects. The main outcome focuses on the proportion of patients achieving clear or almost clear skin after 16 weeks, with ongoing evaluations through 24 months to monitor safety and effectiveness.

Age: 18Years +All Genders
30 locations
A

Actively Recruiting

Non-muscle-invasive bladder cancer NMIBC is a type of bladder tumor that affects the inner lining of the bladder without invading the muscle layer. This research aims to collect and analyze real-world data on how NMIBC is managed and followed up in clinical practice across France. The study seeks to assess the performance of urine tests used to detect tumor recurrence and to understand variations in treatment and patient outcomes. The study is observational and involves collecting medical data from patients being monitored for NMIBC, including results from urine biomarker tests done before biopsies or resections. Urologists participating in the French Urology Association will record findings from regular bladder endoscopic exams and urine test results during routine care visits. Data analysis will focus on the accuracy of urine tests in predicting tumor recurrence and how this varies by tumor characteristics and prior treatments. Participants will have their medical history, treatments, and urine test results entered into a registry at enrollment. During follow-up visits scheduled as part of their personalized care, data on bladder exams and urine tests will be collected. Researchers will evaluate outcomes such as recurrence-free survival and the diagnostic value of urine biomarkers over a five-year period. The study plans to include around 8,000 patients over six years to improve understanding of NMIBC management and follow-up.

Age: 18Years +All Genders
44 locations
O

Actively Recruiting

Researchers are studying adult patients with unresectable or metastatic HER2-low and HER2-ultralow expressing breast cancer who have either received prior chemotherapy in the metastatic setting or have hormone receptor-positive disease not suitable for endocrine therapy. The study aims to observe the real-world use and effects of Trastuzumab deruxtecan T-DXd and conventional chemotherapy in these populations. This observational study collects data without administering any study drugs directly, focusing on patient characteristics, treatment patterns, and safety. Participants will be grouped into those receiving T-DXd according to approved medical guidelines and those treated with conventional chemotherapy, including drugs like capecitabine and paclitaxel. The study records treatment details and the management of any adverse reactions, with Group 2 patients contributing baseline data on conventional chemotherapy. Treatments are given as part of routine clinical care, following the Summary of Product Characteristics, without experimental interventions. During the study, participants treatment courses will be tracked for up to approximately 37 months. Researchers will evaluate the time to next treatment, treatment discontinuation, safety events, and patients impressions of treatment tolerability and quality of life. Data collection includes physician reports, patient diaries, and quality of life questionnaires. This long-term monitoring helps to understand treatment patterns and patient experiences in real-world settings.

Age: 18Years +All Genders
216 locations
C

Actively Recruiting

The TEMPOS-GEniToUrinary Group GETUG study is a multicenter, medico-economic trial comparing two radiation treatmentsbrachytherapy and stereotactic body radiotherapy SBRTin men with low and intermediate risk prostate cancer. The study particularly focuses on erectile dysfunction as a key outcome. Researchers aim to evaluate the cost-utility of SBRT compared to standard Iodine 125 brachytherapy over a period of three years after treatment, including secondary analyses on cost-effectiveness and quality of life up to five years. Participants are assigned to one of two treatment groups. The experimental group receives SBRT delivering 7.25 Gy per fraction, given in five doses for a total of 36.25 Gy to the prostate. Fiducials are implanted in the prostate to help guide treatment using Cyberknife or a conventional linear accelerator with tracking systems. The control group receives brachytherapy with Iodine 125, delivering a total dose of 144 Gy to the prostate. The study includes long-term follow-up to assess erectile dysfunction, genito-urinary and gastro-intestinal toxicities, and quality of life up to five years after treatment. Participants will undergo monitoring and assessments throughout the study period, including evaluations of erectile dysfunction and other side effects. The main outcome measured is the incremental cost-utility ratio comparing SBRT to brachytherapy at three years, with further health economic evaluations at five years. The trial plans to recruit about 240 men across multiple centers over two years, with ongoing data collection on treatment impact, side effects, and quality of life to inform future treatment recommendations and health insurance budgeting.

Age: 18Years +MALEPhase Not Applicable
20 locations
S

Actively Recruiting

Researchers are evaluating the medical benefit of spa therapy on skin and soft tissue fibrosis that occurs as a late reaction at least 6 months after radiotherapy for breast cancer or Upper Aerodigestive Tract UADT cancer. This randomized, controlled, multicenter trial aims to assess improvements in quality of life related to dermatological sequelae of fibrosis. The study focuses on patients with severe late reactions and compares immediate versus delayed spa treatment. The intervention being studied is a dermatologically oriented thermal cure that includes sedative and muscle-relaxing baths, decongestant sprays, and high-pressure thread-like showers using thermal water. Educational workshops on relaxation, sophrology, and hygiene are also part of the therapy. Participants are randomly assigned to receive spa treatment either immediately within 6 weeks of inclusion or after a 6-month delay, allowing comparison of outcomes between early and late treatment groups. Participants will be involved for at least 6 months, during which they will self-assess their dermatological quality of life using the DLQI score and undergo evaluations of generic and cancer-specific quality of life. Additional assessments include self-reported sequelae, radiological examinations of lesions, thickness, and volume, as well as monitoring of treatment and medical consultations. Adverse events and long-term quality of life benefits up to 12 months will be recorded to understand the therapys impact and safety.

Age: 18Years +All GendersPhase Not Applicable
13 locations
C

Actively Recruiting

This research aims to evaluate the quality of life impact of a new cinnamon anti-odor dressing compared to a standard charcoal dressing in patients with malodorous wounds. Malodorous wounds, caused by bacterial activity releasing smelly compounds, can lead to social and psychological discomfort such as shame and isolation. Current treatments like charcoal dressings and antibiotics have limitations, and this study explores a new dressing combining odor adsorption with cinnamon to modify odor perception. Participants will be randomly assigned to use either the cinnamon dressing or the charcoal dressing as a secondary dressing over their primary wound dressing. The dressings will be changed once daily for 14 days. The study involves collecting general wound data and quality of life assessments using the Wound-Qol questionnaire, along with evaluations of discomfort, dressing usability, and appetite at various time points. During the study, participants will assess odor discomfort on days 0, 1, 7, and 14, while caregivers and family will also provide assessments on days 0, 7, and 14. Appetite will be measured using the Simple Evaluation of Food Intake scale. Safety and any dressing-related reactions will be monitored at day 14. The main outcome is the proportion of patients showing a meaningful improvement in quality of life after 14 days of dressing use.

Age: 18Years +All GendersPhase Not Applicable
7 locations
S

Actively Recruiting

Researchers are evaluating the clinical benefit of a complex exome analysis compared to a simple exome analysis for patients with metastatic or locally advanced solid tumors. The study focuses on patients starting their first line of treatment and aims to determine whether the additional genetic information from the complex analysis can guide therapy decisions that would not be possible with the simple analysis. This Phase 2, multicenter study explores how advanced DNA analysis might impact precision medicine in cancer treatment. The study involves performing exome analysis on tumor DNA and constitutional DNA from patients undergoing first-line treatment for their metastatic or locally advanced cancer. The complex analysis provides detailed structural DNA data, including mutational signatures, tumor mutational load, and gene amplifications, which could influence treatment choices. The simple analysis looks at somatic and constitutional mutations without this additional information. The trial does not randomize participants and includes multiple cancer types such as breast, prostate, lung, colorectal, ovarian, sarcoma, and others. Participants will have tumor material available for analysis and will undergo blood tests and assessments according to the study protocol. Researchers will measure the proportion of patients whose therapy is initiated based on information from the complex exome analysis. Patients must have an expected life expectancy of at least six months and be able to follow study procedures. The study includes monitoring clinical outcomes related to treatment decisions guided by genetic findings. Participation continues as per the study timeline, with safety and efficacy assessed through these molecular insights.

Age: 18Years +All GendersPhase 2
12 locations
E

Actively Recruiting

Researchers are studying the effects of combining osteopathy and hypnosis treatments for cancer patients experiencing chronic pain with a significant emotional component. This study aims to compare the impact of osteopathy alone versus osteopathy combined with hypnosis on pain, emotional distress, and quality of life. Osteopathy is known to help with physical comfort and musculoskeletal pain, while hypnosis may reduce anxiety and modulate pain perception, addressing both physical and psychological aspects of pain in cancer care. Participants will be randomly assigned to receive either osteopathy sessions alone or a combination of osteopathy and hypnosis. Osteopathy sessions include a health history discussion, physical assessment, hands-on treatment, and aftercare advice. Hypnosis sessions involve deep relaxation and focused concentration delivered by trained practitioners. The study focuses on supportive care with a parallel design to evaluate the combined approach over several weeks. During the study, participants will attend multiple sessions and assessments over a period of 6 weeks to measure pain and quality of life changes. Emotional distress and patient experience will also be evaluated, including follow-up one month after the final intervention. The study monitors feasibility, acceptability, and clinical value of the combined therapies to improve overall well-being in cancer patients suffering from chronic pain, anxiety, fatigue, and sleep disturbances.

Age: 18Years +All GendersPhase Not Applicable
1 location
O

Actively Recruiting

Researchers are evaluating the effects of innovative and costly anticancer drugs on patients treated at the Rafael Institute, focusing on both safety and effectiveness in real-world use. The study also aims to measure patients quality of life, recognizing that treatment side effects and symptoms impact well-being. This research supports a patient-centered approach, emphasizing personalized and continuous care by a multidisciplinary team to improve overall treatment management. This observational study involves collecting data through standardized and validated self-questionnaires, including the European Organisation for Research and Treatment of Cancer EORTC QLQ-C30 and EQ-5D-5L, along with NCI-PRO-CTCAE questionnaires. Patients receiving non-pharmacological care at the Rafael Institute and treated with selected anticancer drugs are followed over time to document treatment effects and quality of life. Participants will be observed for up to 36 months, with assessments of overall survival, progression-free survival, and incidence of adverse events. Quality of life measurements are taken every six months to track changes over time. Data collection focuses on patients subjective health perceptions, symptoms, and treatment impact, supporting better understanding and management of cancer therapies in everyday practice.

Age: 18Years +All Genders
1 location

1-10 of 19

1